Mepolizumab as a steroid-sparing treatment option in patients with Churg-Strauss syndrome

Development and validation of a questionnaire to measure asthma control

Juniper, E. F., O′byrne, P. M., Guyatt, G. H., Ferrie, P. J., & King, D. R. (1999) · European Respiratory Journal · doi:10.1034/j.1399-3003.1999.14d29.x · Cited by 2,473

The American College of Rheumatology 1990 criteria for the classification of churg‐strauss syndrome (allergic granulomatosis and angiitis)

Masi, A. T., Hunder, G. G., Lie, J. T., Michel, B. A., Bloch, D. A., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330806 · Cited by 2,212

Mepolizumab and Exacerbations of Refractory Eosinophilic Asthma

Haldar, P., Brightling, C. E., Hargadon, B., Gupta, S., Monteiro, W. R., Sousa, A. R., Marshall, R. P., Bradding, P., Green, R. H., Wardlaw, A. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808991 · Cited by 1,873

Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsìveness, and the late asthmatic response

Leckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A., Cowley, H., Chung, K. F., Djukanović, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,810

Mepolizumab for Prednisone-Dependent Asthma with Sputum Eosinophilia

Nair, P. K., Pizzichini, M. M. M., Kjarsgaard, M., Inman, M. D., Efthimiadis, A., Pizzichini, E., Hargreave, F. E., & O’Byrne, P. M. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805435 · Cited by 1,346

Birmingham Vasculitis Activity Score (BVAS) in systemic necrotizing vasculitis.

Luqmani, R. A., BACON, P. A., Moots, R. J., Janssen, B. A., Pall, A. A., Emery, P., Savage, C. O. S., & Adu, D. (1994) · PubMed · Cited by 1,056

Interleukin-5, eosinophils, and disease

Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.bloodjournal79123101 · Cited by 972

Interleukin-5, eosinophils, and disease

Sanderson, C. (1992) · Blood · doi:10.1182/blood.v79.12.3101.3101 · Cited by 860

Eosinophil's Role Remains Uncertain as Anti–Interleukin-5 only Partially Depletes Numbers in Asthmatic Airway

Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B., & Robinson, D. S. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200208-789oc · Cited by 808

A Study to Evaluate Safety and Efficacy of Mepolizumab in Patients with Moderate Persistent Asthma

Flood-Page, P. T., Swenson, C. A., Faiferman, I., Matthews, J. G., Williams, M. J. A., Brannick, L., Robinson, D. S., Wenzel, S. E., Busse, W. W., Hansel, T. T., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200701-085oc · Cited by 750

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

Wechsler, M. E., Akuthota, P., Jayne, D. G., Khoury, P., Klion, A. D., Langford, C. A., Merkel, P. A., Moosig, F., Specks, U., Cid, M. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1702079 · Cited by 1,091

International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis

Wise, S. K., Lin, S. Y., Toskala, E., Orlandi, R. R., Akdis, C. A., Alt, J. A., Azar, A., Baroody, F. M., Bachert, C., Canonica, G. W., et al. (2018) · International Forum of Allergy & Rhinology · doi:10.1002/alr.22073 · Cited by 557

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss) (EGPA) Consensus Task Force recommendations for evaluation and management

Groh, M., Pagnoux, C., Baldini, C., Bel, E., Bottero, P., Cottin, V., Dalhoff, K., Dunogué, B., Gross, W., Holle, J., et al. (2015) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2015.04.022 · Cited by 476

An Antibody Against IL-5 Reduces Numbers of Esophageal Intraepithelial Eosinophils in Children With Eosinophilic Esophagitis

Assa’ad, A., Gupta, S. K., Collins, M. H., Thomson, M. A., Heath, A. T., Smith, D. A., Perschy, T. L., Jurgensen, C. H., Ortega, H. G., & Aceves, S. S. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.07.044 · Cited by 438

Targeting cytokines to treat asthma and chronic obstructive pulmonary disease

Barnes, P. J. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0006-6 · Cited by 432

Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis

Emmi, G., Bettiol, A., Gelain, E., Bajema, I. M., Berti, A., Burns, S., Cid, M. C., Tervaert, J. W. C., Cottin, V., Durante, E., et al. (2023) · Nature Reviews Rheumatology · doi:10.1038/s41584-023-00958-w · Cited by 343

Churg–Strauss syndrome

Greco, A., Rizzo, M. I., VIRGILIO, A. D., Gallo, A., Fusconi, M., Ruoppolo, G., ALTISSIMI, G., & VINCENTIIS, M. D. (2014) · Autoimmunity Reviews · doi:10.1016/j.autrev.2014.12.004 · Cited by 297

Eosinophilic granulomatosis with polyangiitis ( C hurg– S trauss): state of the art

Vaglio, A., Buzio, C., & Zwerina, J. (2013) · Allergy · doi:10.1111/all.12088 · Cited by 283

A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg–Strauss, EGPA): monocentric experiences in 150 patients

Moosig, F., Bremer, J. P., Hellmich, B., Holle, J. U., Holl-Ulrich, K., Laudien, M., Matthis, C., Metzler, C., Nölle, B., Richardt, G., et al. (2013) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2012-201531 · Cited by 279

Biomarkers for severe eosinophilic asthma

Yancey, S. W., Keene, O. N., Albers, F. C., Ortega, H. G., Bates, S., Bleecker, E. R., & Pavord, I. D. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2017.10.005 · Cited by 229

Molecular and clinical rationale for therapeutic targeting of interleukin‐5 and its receptor

Molfino, N. A., Gossage, D. L., Kolbeck, R., Parker, J. M., & Geba, G. P. (2011) · Clinical & Experimental Allergy · doi:10.1111/j.1365-2222.2011.03854.x · Cited by 217

Eosinophilic Granulomatosis with Polyangiitis: An Overview

Gioffredi, A., Maritati, F., Oliva, E., & Buzio, C. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00549 · Cited by 217

Targeting Interleukin-5 in Refractory and Relapsing Churg–Strauss Syndrome

Moosig, F., Gross, W. L., Herrmann, K., Bremer, J. P., & Hellmich, B. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-5-201109060-00026 · Cited by 205

Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management

Trivioli, G., Terrier, B., & Vaglio, A. (2019) · Lara D. Veeken · doi:10.1093/rheumatology/kez570 · Cited by 193

Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma

Roufosse, F. E. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00049 · Cited by 191

Eosinophils in vasculitis: characteristics and roles in pathogenesis

Khoury, P., Grayson, P. C., & Klion, A. D. (2014) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2014.98 · Cited by 182

Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders

Varricchi, G., Bagnasco, D., Borriello, F., Heffler, E. M., & Canonica, G. W. (2016) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000251 · Cited by 178

Eosinophilic granulomatosis with polyangiitis: A review

White, J., & Dubey, S. (2022) · Autoimmunity Reviews · doi:10.1016/j.autrev.2022.103219 · Cited by 178

Severe asthma: Advances in current management and future therapy

Barnes, P. J. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.11.006 · Cited by 174

Advances in mechanisms of asthma, allergy, and immunology in 2010

Broide, D. H., Finkelman, F. D., Bochner, B. S., & Rothenberg, M. E. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.01.027 · Cited by 172

Eosinophils in Autoimmune Diseases

Diny, N. L., Rose, N. R., & Čiháková, D. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00484 · Cited by 172

Anti–IL-5 therapy reduces mast cell and IL-9 cell numbers in pediatric patients with eosinophilic esophagitis

Otani, I. M., Anilkumar, A. A., Newbury, R., Bhagat, M., Beppu, L. Y., Dohil, R., Broide, D. H., & Aceves, S. S. (2013) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2013.02.042 · Cited by 161

New pathophysiological insights and treatment of ANCA-associated vasculitis

Wilde, B., van Paassen, P., Witzke, O., & Tervaert, J. W. C. (2010) · Kidney International · doi:10.1038/ki.2010.472 · Cited by 151

Evaluation of clinical benefit from treatment with mepolizumab for patients with eosinophilic granulomatosis with polyangiitis

Steinfeld, J., Bradford, E., Brown, J., Mallett, S. A., Yancey, S. W., Akuthota, P., Cid, M. C., Gleich, G. J., Jayne, D. R. W., Khoury, P., et al. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.11.041 · Cited by 151

Eosinophilic Lung Diseases

Cottin, V. (2016) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2016.04.015 · Cited by 146

Eosinophilic granulomatosis with polyangiitis (Churg–Strauss)

Mahr, A., Moosig, F., Neumann, T. E., Szczeklik, W., Taillé, C., Vaglio, A., & Zwerina, J. (2013) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000015 · Cited by 145

Pathophysiology of asthma: What has our current understanding taught us about new therapeutic approaches?

Holgate, S. T. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.06.052 · Cited by 136

Eosinophil Knockout Humans: Uncovering the Role of Eosinophils Through Eosinophil-Directed Biological Therapies

Jacobsen, E. A., Jackson, D. J., Heffler, E. M., Mathur, S. K., Bredenoord, A. J., Pavord, I. D., Akuthota, P., Roufosse, F. E., & Rothenberg, M. E. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-093019-125918 · Cited by 136

Animal models of asthma: value, limitations and opportunities for alternative approaches

Holmes, A. M., Solari, R. C. E., & Holgate, S. T. (2011) · Drug Discovery Today · doi:10.1016/j.drudis.2011.05.014 · Cited by 136

Increased production of IL-5 and dominant Th2-type response in airways of Churg–Strauss syndrome patients

Jakieła, B., Szczeklik, W., Plutecka, H., Sokołowska, B. M., Mastalerz, L., Sanak, M., Bazan‐Socha, S., Szczeklik, A., & Musiał, J. (2012) · Lara D. Veeken · doi:10.1093/rheumatology/kes171 · Cited by 123

Pharmacokinetics and Pharmacodynamics of Mepolizumab, an Anti-Interleukin-5 Monoclonal Antibody

Smith, D. A., Minthorn, E. A., & Beerahee, M. (2011) · Clinical Pharmacokinetics · doi:10.2165/11584340-000000000-00000 · Cited by 117

From DREAM to REALITI‐A and beyond: Mepolizumab for the treatment of eosinophil‐driven diseases

Pavord, I. D., Bel, E. H., BOURDIN, A. A., Chan, R. H., Han, J. K., Keene, O. N., Liu, M. C., Martin, N., Papi, A. A., Roufosse, F. E., et al. (2021) · Allergy · doi:10.1111/all.15056 · Cited by 116

Eosinophilic Pneumonias

Akuthota, P., & Weller, P. F. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.00025-12 · Cited by 115

What targeting eosinophils has taught us about their role in diseases

Bochner, B. S., & Gleich, G. J. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.02.026 · Cited by 110

Eosinophils and eosinophilic immune dysfunction in health and disease

Jackson, D. J., Akuthota, P., & Roufosse, F. E. (2022) · European Respiratory Review · doi:10.1183/16000617.0150-2021 · Cited by 112

Anti‐IgE Monoclonal Antibody (Omalizumab) in Refractory and Relapsing Eosinophilic Granulomatosis With Polyangiitis (Churg‐Strauss): Data on Seventeen Patients

Jachiet, M., Samson, M., Cottin, V., Kahn, J., Guenno, G. L., Bonniaud, P., Devilliers, H., Bouillet, L., Gondouin, A., Makhlouf, F., et al. (2016) · Arthritis & Rheumatology · doi:10.1002/art.39663 · Cited by 106

EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders

Boyman, O., Kaegi, C., Akdiş, M., Bavbek, S., Bossios, A., Chatzipetrou, A., Eiwegger, T., Firinu, D., Harr, T., Knol, E. F., et al. (2015) · Allergy · doi:10.1111/all.12616 · Cited by 105

Biologic Therapies Targeting Eosinophils: Current Status and Future Prospects

Legrand, F., & Klion, A. D. (2015) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2015.01.013 · Cited by 103

Allergic Comorbidity in Eosinophilic Esophagitis: Mechanistic Relevance and Clinical Implications

Capucilli, P., & Hill, D. A. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08733-0 · Cited by 109

Novel targeted therapies for eosinophilic disorders

Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., Ortega, H. G., Patel, J., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.027 · Cited by 100

Churg–Strauss syndrome

Vaglio, A., Moosig, F., & Zwerina, J. (2011) · Current Opinion in Rheumatology · doi:10.1097/bor.0b013e32834d85ce · Cited by 95

Long-term clinical outcomes of high-dose mepolizumab treatment for hypereosinophilic syndrome

Kuang, F. L., Fay, M. P., Ware, J., Wetzler, L., Holland-Thomas, N., Brown, T., Ortega, H., Steinfeld, J., Khoury, P., & Klion, A. D. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.033 · Cited by 94

Eosinophilic granulomatosis with polyangiitis – Advances in pathogenesis, diagnosis, and treatment

Fijołek, J., & Radzikowska, E. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1145257 · Cited by 94

Lung involvement in ANCA-associated vasculitis

Sacoto, G., Boukhlal, S., Specks, U., Flores-Suárez, L. F., & Cornec, D. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104039 · Cited by 99

Anti-IL5 therapy for asthma and beyond

Mukherjee, M., Sehmi, R., & Nair, P. K. (2014) · World Allergy Organization Journal · doi:10.1186/1939-4551-7-32 · Cited by 90

Eosinophils and Disease Pathogenesis

Akuthota, P., & Weller, P. F. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.01.005 · Cited by 88

Eosinophilic Lung Diseases

Cottin, V., & Cordier, J.-F. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.007 · Cited by 88

Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma

Bagnasco, D., Ferrando, M., Varricchi, G., Puggioni, F., Passalacqua, G., & Canonica, G. W. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00135 · Cited by 87

Clinical reviews in allergy and immunology

Leung, D. Y. M., Ledford, D. K., Wechsler, M. E., Fulkerson, P. C., Bochner, B. S., Gauvreau, G. M., Gleich, G. J., Henkel, T., Kolbeck, R., Mathur, S. K., et al. (2012) · Cited by 87

Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab

Pouliquen, I. J., Kornmann, O., Barton, S. V., Price, J. A., & Ortega, H. G. (2015) · International Journal of Clinical Pharmacology and Therapeutics · doi:10.5414/cp202446 · Cited by 85

S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

Schirmer, J. H., Aries, P. M., de Groot, K., Hellmich, B., Holle, J. U., Kneitz, C., Kötter, I., Lamprecht, P., Müller‐Ladner, U., Reinhold‐Keller, E., et al. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0394-1 · Cited by 82

Eosinophils: Friends or Foes?

Chusid, M. J. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.04.031 · Cited by 81

The Immunologic Mechanisms of Eosinophilic Esophagitis

Hill, D. A., & Spergel, J. M. (2016) · Current Allergy and Asthma Reports · doi:10.1007/s11882-015-0592-3 · Cited by 82

Gastrointestinal aspects of vasculitides

Soowamber, M. L., Weizman, A. V., & Pagnoux, C. (2016) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.179 · Cited by 77

Treatment of Eosinophilic Granulomatosis with Polyangiitis: A Review

Raffray, L., & Guillevin, L. (2018) · Drugs · doi:10.1007/s40265-018-0920-8 · Cited by 75

Mepolizumab: First Global Approval

Keating, G. M. (2015) · Drugs · doi:10.1007/s40265-015-0513-8 · Cited by 74

French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)

Terrier, B., Darbon, R., Durel, C., HACHULLA, E., Karras, A., Maillard, H., Papo, T., Puéchal, X., Pugnet, G., Quéméneur, T., et al. (2020) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-020-01621-3 · Cited by 72

CanVasc Recommendations for the Management of Antineutrophil Cytoplasm Antibody-associated Vasculitides

McGeoch, L., Twilt, M., Famorca, L., Bakowsky, V., Barra, L., Benseler, S. M., Cabral, D. A., Carette, S., Cox, G., Dhindsa, N., et al. (2015) · The Journal of Rheumatology · doi:10.3899/jrheum.150376 · Cited by 72

Tailored therapy for severe asthma

Menzella, F., Lusuardi, M., Galeone, C., & Zucchi, L. (2015) · Multidisciplinary Respiratory Medicine · doi:10.1186/2049-6958-10-1 · Cited by 64

Progress in treatment of ANCA-associated vasculitis

Smith, R., Jones, R. B., & Jayne, D. R. W. (2012) · Arthritis Research & Therapy · doi:10.1186/ar3797 · Cited by 63

IL-5 receptor α levels in patients with marked eosinophilia or mastocytosis

Wilson, T. M., Marić, I., Shukla, J., Brown, M. R., Santos, C. S., Šimáková, O., Khoury, P., Fay, M. P., Kozhich, A. T., Kolbeck, R., et al. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.05.032 · Cited by 61

Omalizumab as a Steroid-Sparing Agent in Chronic Eosinophilic Pneumonia

Kaya, H., Gümüş, S., Uçar, E., Aydoğan, M., Muşabak, U., Tozkoparan, E., & Bilgiç, H. (2012) · CHEST Journal · doi:10.1378/chest.11-1881 · Cited by 60

Omalizumab in patients with eosinophilic granulomatosis with polyangiitis: a 36-month follow-up study

Detoraki, A., Capua, L. D., Varricchi, G., Genovese, A., Marone, G., & Spadaro, G. (2015) · Journal of Asthma · doi:10.3109/02770903.2015.1081700 · Cited by 59

Treatment of ANCA-associated vasculitides (AAV)

Holle, J. U., & Gross, W. L. (2012) · Autoimmunity Reviews · doi:10.1016/j.autrev.2012.08.007 · Cited by 57

Mepolizumab in eosinophilic disorders

Abonia, J. P., & Putnam, P. E. (2011) · Expert Review of Clinical Immunology · doi:10.1586/eci.11.27 · Cited by 56

Workshop report from the National Institutes of Health Taskforce on the Research Needs of Eosinophil-Associated Diseases (TREAD)

Bochner, B. S., Book, W., Busse, W. W., Butterfield, J. H., Furuta, G. T., Gleich, G. J., Klion, A. D., Lee, J. J., Leiferman, K. M., Minnicozzi, M., et al. (2012) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2012.07.024 · Cited by 55

Eosinophilic granulomatosis with polyangiitis in childhood: retrospective experience from a tertiary referral centre in the UK

Eleftheriou, D., Gale, H., Pilkington, C., Fenton, M. J., Sebire, N. J., & Brogan, P. A. (2016) · Lara D. Veeken · doi:10.1093/rheumatology/kew029 · Cited by 55

Profile of anti-IL-5 mAb mepolizumab in the treatment of severe refractory asthma and hypereosinophilic diseases

Menzella, F., Lusuardi, M., Galeone, C., Taddei, S., & Zucchi, L. (2015) · Journal of Asthma and Allergy · doi:10.2147/jaa.s40244 · Cited by 54

Biologics for the treatment of autoimmune renal diseases

Holdsworth, S. R., Gan, P., & Kitching, A. R. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2016.18 · Cited by 53

Novel Targeted Therapies for Eosinophil-Associated Diseases and Allergy

Radonjic‐Hoesli, S., Valent, P., Klion, A. D., Wechsler, M. E., & Simon, H. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124407 · Cited by 52

Mepolizumab as the first targeted treatment for eosinophilic granulomatosis with polyangiitis: a review of current evidence and potential place in therapy

Faverio, P., Bonaiti, G., Bini, F., Vaghi, A., & Pesci, A. (2018) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s159949 · Cited by 51

Diagnosis and treatment of cutaneous leukocytoclastic vasculitis

Gota, C. E., & Calabrese, L. H. (2013) · International Journal of Clinical Rheumatology · doi:10.2217/ijr.12.79 · Cited by 50

Biologic Agents for the Treatment of Hypereosinophilic Syndromes

Kuang, F. L., & Klion, A. D. (2017) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2017.08.001 · Cited by 50

Low-Dose Mepolizumab Effectiveness in Patients Suffering From Eosinophilic Granulomatosis With Polyangiitis

Vultaggio, A., Nencini, F., Bormioli, S., Vivarelli, E., Dies, L., Rossi, O., Parronchi, P., Maggi, E., & Matucci, A. (2020) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2020.12.5.885 · Cited by 50

Eosinophilia and Kidney Disease: More than Just an Incidental Finding?

Gauckler, P., Shin, J., Mayer, G., & Kronbichler, A. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7120529 · Cited by 45

Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease

Berti, A., Boukhlal, S., Groh, M., & Cornec, D. (2019) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2019.1697678 · Cited by 48

Personalized Medicine in Allergy

Ferrando, M., Bagnasco, D., Varricchi, G., Bernardi, S., Bragantini, A., Passalacqua, G., & Canonica, G. W. (2016) · Allergy Asthma and Immunology Research · doi:10.4168/aair.2017.9.1.15 · Cited by 47

Biological therapy for systemic vasculitis: A systematic review

Silva-Fernández, L., Loza, E., Martínez-Taboada, V. M., Blanco, R., Rúa‐Figueroa, Í., Pego‐Reigosa, J. M., & Muñoz‐Fernández, S. (2013) · Seminars in Arthritis and Rheumatism · doi:10.1016/j.semarthrit.2013.07.010 · Cited by 46

Anti-interleukin-5 antibody therapy in asthma and allerges

Corren, J. (2011) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0b013e32834c3d30 · Cited by 46

S1-Leitlinie Diagnostik und Therapie der ANCA-assoziierten Vaskulitiden

Schirmer, J. H., & Moosig, F. (2017) · Zeitschrift für Rheumatologie · doi:10.1007/s00393-017-0393-2 · Cited by 46

Updates for the treatment of EGPA

Raffray, L., & Guillevin, L. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104036 · Cited by 40

Real-life evidence of low-dose mepolizumab efficacy in EGPA: a case series

Detoraki, A., Tremante, E., Poto, R., Morelli, E., Quaremba, G., Granata, F., Romano, A., Mormile, I., Rossi, F. W., de Paulis, A., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01775-z · Cited by 43

Eosinophils: Offenders or General Bystanders in Allergic Airway Disease and Pulmonary Immunity?

Akuthota, P., Xenakis, J. J., & Weller, P. F. (2011) · Journal of Innate Immunity · doi:10.1159/000323433 · Cited by 38

Update on the Management of Respiratory Manifestations of the Antineutrophil Cytoplasmic Antibodies-Associated Vasculitides

Thompson, G. E., & Specks, U. (2019) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2019.05.012 · Cited by 38

Anti-IL-5 Pathway Agents in Eosinophilic-Associated Disorders Across the Lifespan

Lombardi, C., Comberiati, P., Ridolo, E., Cottini, M., Yacoub, M., Casagrande, S., Riccò, M., Bottazzoli, M., & Berti, A. (2024) · Drugs · doi:10.1007/s40265-024-02037-0 · Cited by 35

Therapeutic Approaches to Patients With Hypereosinophilic Syndromes

Simon, H., & Klion, A. D. (2012) · Seminars in Hematology · doi:10.1053/j.seminhematol.2012.01.002 · Cited by 35

Hypereosinophilic syndrome

Hsieh, F. H. (2014) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2014.03.004 · Cited by 34

Insight into IL-5 as a Potential Target for the Treatment of Allergic Diseases

Antosz, K., Batko, J., Błażejewska, M., Gawor, A., Sleziak, J., & Gomułka, K. (2024) · Biomedicines · doi:10.3390/biomedicines12071531 · Cited by 33

Churg-Strauss Syndrome: An Update

Abril, A. (2011) · Current Rheumatology Reports · doi:10.1007/s11926-011-0205-7 · Cited by 33

ANCA-associated vasculitides: Recommendations of the French Vasculitis Study Group on the use of immunosuppressants and biotherapies for remission induction and maintenance

Terrier, B., Charles, P., Aumaître, O., Bélot, A., Bonnotte, B., Crabol, Y., Durel, C., Ebbo, M., Jourde‐Chiche, N., Lega, J., et al. (2020) · La Presse Médicale · doi:10.1016/j.lpm.2020.104031 · Cited by 33

Control of inflammatory heart disease by CD4+ T cells

Barin, J. G., & Čiháková, D. (2013) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12134 · Cited by 34

Biomarkers of eosinophil involvement in allergic and eosinophilic diseases: Review of phenotypic and serum markers including a novel assay to quantify levels of soluble Siglec-8

Na, H. J., Hamilton, R. G., Klion, A. D., & Bochner, B. S. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.05.017 · Cited by 33

Eosinophilia in Rheumatologic/Vascular Disorders

Tamaki, H., Chatterjee, S., & Langford, C. A. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.05.001 · Cited by 30

Targeted Anti-IL-5 Therapies and Future Therapeutics for Hypereosinophilic Syndrome and Rare Eosinophilic Conditions

Harish, A., & Schwartz, S. A. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08775-4 · Cited by 30

Current Landscape of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis

Lally, L., & Spiera, R. (2014) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2014.09.003 · Cited by 28

Targeting eosinophils: severe asthma and beyond

Caminati, M., Menzella, F., Guidolin, L., & Senna, G. (2019) · Drugs in Context · doi:10.7573/dic.212587 · Cited by 27

Biologics for the Treatment of Allergic Conditions: Eosinophil Disorders

Olivieri, B., Tinazzi, E., Caminati, M., & Lunardi, C. (2020) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2020.07.001 · Cited by 27

Novel Therapies for Eosinophilic Disorders

Bochner, B. S. (2015) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2015.05.007 · Cited by 27

Clinical Features of Patients with Active Eosinophilic Granulomatosis with Polyangiitis Successfully Treated with Mepolizumab

Tsurikisawa, N., Oshikata, C., Watanabe, M., Fukuda, N., Yamaguchi, T., Kiyohara, H., & Kaneko, T. (2021) · International Archives of Allergy and Immunology · doi:10.1159/000514505 · Cited by 26

Eosinophilic Lung Diseases

Pérez, E. R. F., Olson, A. L., & Frankel, S. K. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2011.08.006 · Cited by 26

Mepolizumab as a Steroid-Sparing Treatment in the Churg Strauss Syndrome.

Sh, K., Israel, E., Oren, E., & Wechsler, M. E. (2009) · doi:10.1164/ajrccm-conference.2009.179.1_meetingabstracts.a5468 · Cited by 2

Oral glucocorticoid-sparing effects of mepolizumab. A real-life study.

Bjerrum, A., Schmid, J., & Skjold, T. (2018) · doi:10.1183/13993003.congress-2018.pa601 · Cited by 2

Efficacy and safety of mepolizumab in eosinophilic granulomatosis with polyangiitis: Insights from real-life cases and literature analysis.

Cassone, G., Sebastiani, M., Cataleta, P., Olivi, E., Gurioli, C., Cerri, S., Beghé, B., Giuggioli, D., & Manfredi, A. (2025) · Sarcoidosis vasculitis and diffuse lung diseases · doi:10.36141/svdld.v42i1.16311 · Cited by 1

Rationale and design of a placebo-controlled trial to evaluate the steroid-sparing effects of anti-IL5 monoclonal antibody (mepolizumab): Focus on cutaneous outcomes in patients with hypereosinophilic syndrome (HES)

(2007) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2006.10.347

Late-breaking abstract: Oral corticosteroid-sparing effect of mepolizumab in severe eosinophilic asthma: The SIRIUS study

Bel, E. H., Wenzel, S., Thompson, P. J., Prazma, C. M., Keene, O. N., Yancey, S., Ortega, H., & Pavord, I. D. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.2907 · Cited by 10